About Histogen
Histogen is a company based in San Diego (United States) founded in 2007 by Gail Naughton. Histogen has raised $51.4 million across 9 funding rounds from investors including Secure Medical and Angus Mitchell. Histogen operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
- Headquarter San Diego, United States
- Founders Gail Naughton
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website histogen.com
- Social LinkedIn
- Legal Name Histogen Inc
- Annual Revenue$3.77 M (USD)265.21as on Dec 31, 2022
- Net Profit-$10.62 M (USD)28.96as on Dec 31, 2022
- EBITDA-$10.5 M (USD)31.62as on Dec 31, 2022
- Total Equity Funding$51.4M (USD)
in 9 rounds
- Latest Funding Round$5M (USD), Post-IPO
Jul 2022
- InvestorsSecure Medical
& 1 more
Funding Insights of Histogen
Histogen has successfully raised a total of $51.4M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.4M
- Total Rounds 9
- Last Round Post-IPO — $5M
- First Round $9.49M
(Dec 2007)
- Investors Count 2
All 9 funding rounds of Histogen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $5M | Post-IPO | – | – | – |
| Mar 2022 | – | Post-IPO | – | – | – |
| Dec 2021 | $3.5M | Post-IPO | – | – | – |
| Nov 2020 | $189,208 | Series A | – | – | – |
| Sep 2019 | $15.33M | Series C | – | – | – |
| Aug 2016 | $6M | Series A | – | – | – |
| Jun 2015 | $10.39M | Series B | – | – | – |
| Dec 2010 | $10M | Series A | – | Secure Medical | |
| Dec 2007 | $9.49M | Series A | – | – | – |
2 investors in total: 1 institutional and 1 angel.
Investors in Histogen
Histogen has secured backing from 2 investors, including institutional and angel investors. Prominent investors backing the company include Secure Medical and Angus Mitchell.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Offers telemedicine for prescribing medications and treating common ailments online. | 2006 | securemedical.com | Tempe, United States | |
AM Angus Mitchell | - | – | unknown_a9997d3583be43179 | - |
Investor details for Histogen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Histogen
10 people are tracked at Histogen (4 in leadership, 5 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Gail Naughton | Founder & CEO | Leadership |
Susan A. Knudson | Executive Vice President, Chief Financial Officer | Leadership |
Steven J. Mento | Executive Chairman, Interim President & CEO | Leadership |
Jessie A. | Director Of Quality - Regenerative Medicine (clinical/clia/ops/quality) | Leadership |
Daniel L. Kisner | Director | Board & advisors |
Jonathan Jackson | Director | Board & advisors |
Rochelle Fuhrmann | Director | Board & advisors |
Susan Windham-Bannister | Director | Board & advisors |
David H. Crean | Chairman | Board & advisors |
Joyce Reyes | SVP of Regulatory, Quality & Technical Operations | Team |
Complete people profiles for Histogen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Histogen
Histogen is a publicly listed company on the OTC with ticker symbol HSTOQ in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Apr 2021
- Listed onLSE: 0A8J
- Listed entityHISTOGEN INC
- Exchange sectorHealth technology
- ISINUS43358Y2028
- Share price$0.00 (+316.67% on the day) · 2026-01-05
- Market capitalisation$5,340.00
- Volume (last session)1,625
- Analyst consensusNeutral
Financials of Histogen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | $3.8M | -$10.6M | -$10.5M |
| 2021 | $1.0M | -$14.9M | -$15.4M |
| 2020 | $2.1M | -$18.8M | -$11.6M |
Detailed financial statements for Histogen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Histogen
4 dated milestones of Histogen across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Histogen is founded.
- Funding First funding round of $9.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $5.0M.
Competitors of Histogen
Histogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| dermavant.com | 2016 | Phoenix, United States | $160M | – | Small molecule therapeutics for inflammatory skin diseases are developed. | |
| sol-gel.com | 1998 | United States | $9M | – | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. | |
| bauschhealth.com | 1960 | Laval, Canada | – | 808 | Therapeutics for multiple diseases including dermatology and neurology are developed. | |
| hugel.co.kr | 2001 | Chuncheon-si, South Korea | – | – | Therapeutics in aesthetics are developed, including botulinum toxin products. | |
| kythera.com | 2005 | Calabasas, United States | $144.82M | 113 | Prescription products for aesthetic medicine are developed and commercialized. | |
| sofregen.com | 2014 | Medford, United States | $17.8M | 8 | Silk-derived biomaterials are developed for soft tissue repair in surgery. | |
| pyramidbio.com | 2015 | Waltham, United States | $71.19M | 3 | Small molecules are developed for dermatology and oncology treatments. |
Detailed competitors of Histogen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Histogen
Websites that share an audience with Histogen (histogen.com).
- Global rank#13,671,016
among all websites
- Category rank#8,472
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.2
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with Histogen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| intermune.com | 100% | – | – | View details | |
smartchoicestemcell.com | smartchoicestemcell.com | 70% | – | – | – |
ascpt.org | ascpt.org | 63% | – | #1,430,900 | – |
| hairlosscure2020.com | 63% | – | #690,734 | View details | |
community.parentprojectmd.org | community.parentprojectmd.org | 62% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Histogen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Histogen
Complete news archive for Histogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Histogen
10 companies that operate in the same segment as Histogen (Dermatology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Developer of drugs for treating dermatology diseases | 1908 | Copenhagen, Denmark | USD 560.38 M | – | – | |
Skincare, beauty, and wellness services provided by VLCC across multiple countries. | 1989 | Delhi, Delhi, India | – | – | – | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Immunotherapeutic solutions for dermatological conditions are developed. | 2016 | Westlake Village, California, United States | USD 94.5 M | USD 376.07 M | 342 | |
Targeted small molecules are developed for oncology treatments. | 2010 | Singapore, Singapore | USD 100 M | – | – | |
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured. | 2014 | Pune, Maharashtra, India | USD 25.97 M | USD 18.15 M | 508 | |
Novel dermatologic therapies are developed for skin conditions. | 2012 | Malvern, Pennsylvania, United States | USD 82 M | USD 7.83 M | 64 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Histogen
Histogen was founded in 2007.
Histogen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Gail Naughton is the current CEO of Histogen. They have also founded this company.
Histogen is a funded company, having raised a total of $51.4M across 9 funding rounds to date. The company's 1st funding round was a Series A of $9.49M, raised on Dec 2007.
Annual revenue of Histogen is $3.77M as on Dec 31, 2022.
Developer of regenerative medicine using embryonic cell alternatives. The companys bioreactors mimic the embryonic environment, newborn cells are encouraged to naturally produce the vital proteins and growth factors. Histogen has two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human Extracellular Matrix (ECM) material, ExCeltrix. It is exploring indications in aesthetics, specifically hair loss, and oncology.
Histogen's top competitors include Revance Therapeutics, Dermavant and Bausch Health.
Yes, Histogen is publicly traded on OTC under the ticker symbol HSTOQ.
Histogen has 2 investors. Key investors include Secure Medical, and Angus Mitchell.
Histogen operates through Histogen, Inc..